P2.09-24 Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD by Li, M.S., Lee, K.W.C., Loong, H.H.F., Lam, K.C., Mok, F.S.T., Lau, Y.M., Chan, K.P., Mok, K.K.S., Ng, J.T.Y., Chen, A.C.C., Wong, W.K.Y., Lam, B.H.W., Chen, O.H., Mok, T.S.K.

Get full text